TRANSLATIONAL STRATEGIES
DEAD

Serial Number

98830622

Owner

Translational Cures, LLC

Attorney

David R. Schaffer

Filing Date

Oct 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TRANSLATIONAL STRATEGIES Trademark

Serial Number: 98830622

TRANSLATIONAL STRATEGIES is a trademark filed by Translational Cures, LLC on October 31, 2024. The trademark is classified under Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Translational Cures, LLC (3 trademarks)

1209 Orange Street
Wilmington, DE 19801

Entity Type: 16

Trademark Details

Filing Date

October 31, 2024

Registration Date

Not Registered

Goods & Services

Providing education, training, and workshop services, namely, conducting seminars and workshops in the fields of regulatory science, pharmaceuticals, biotechnology, drugs, chemicals, medical products, and consumer products; Training programs in regulatory science, pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product research methods

Providing custom manufacturing services

Providing Business Consulting and Strategic Services; Business consulting services in the pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product industries

Providing regulatory consulting and legal compliance services; Providing regulatory consulting in the pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product industries; Toxicity testing of pharmaceutical, biotechnology, drug, chemical, medical, and consumer products for medical purposes

Providing toxicity testing services, namely, testing of chemicals for others; Toxicity testing as part of the research and development of pharmaceutical, biotechnology, drug, chemical, medical, and consumer products

Providing online non-downloadable software and artificial intelligence (AI) tools for research and consulting; Non-downloadable software for pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product research and consulting; Non-downloadable computer modeling, simulation and artificial intelligence software tools for use in pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product research and development; Pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product development services; Consulting services, namely, product development research services in the fields of pharmaceutical, biotechnology, drug, chemical, medical products, and consumer products; Consulting services in the fields of pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product development research and development; Development and establishment of testing specifications and procedures for pharmaceutical, biotechnology, drug, chemical, medical product, and consumer product industries; Development and establishment of testing specifications and procedures in the fields of pharmaceuticals, biotechnology, drugs, chemicals, medical products, and consumer products; Medical and scientific research in the fields of pharmaceutical, biotechnology, drug, chemical, medical products, and consumer products; Medical and scientific research and development using artificial intelligence in the fields of pharmaceutical, biotechnology, drug, chemical, medical products, and consumer products; Research and development in the fields of pharmaceutical, biotechnology, drug, chemical, medical products, and consumer products; Research and development using artificial intelligence in the fields of pharmaceutical, biotechnology, drug, chemical, medical products, and consumer products; Providing contract scientific research for others; Providing contract research in the pharmaceutical, drug, chemical, medical product, and consumer product industries for others

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 18, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 18, 2025 ABN2
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
May 1, 2025 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
May 1, 2025 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
May 1, 2025 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
May 1, 2025 CPEA
ASSIGNED TO EXAMINER
Apr 28, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 28, 2025 NWOS
NEW APPLICATION ENTERED
Oct 31, 2024 NWAP